{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:59:13Z","timestamp":1779263953879,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40119-020-00181-8","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T22:02:26Z","timestamp":1592690546000},"page":"447-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies"],"prefix":"10.1007","volume":"9","author":[{"given":"Michael J.","family":"Koren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter H.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer G.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hucko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Antonio G.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex N.","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ransi","family":"Somaratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,20]]},"reference":[{"key":"181_CR1","doi-asserted-by":"crossref","unstructured":"The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365\u201374.","DOI":"10.1001\/jama.251.3.365"},{"key":"181_CR2","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"181_CR3","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581\u201390.","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"181_CR4","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615\u201322.","journal-title":"JAMA"},{"key":"181_CR5","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0002-9149(02)02306-8","volume":"89","author":"S Kinlay","year":"2002","unstructured":"Kinlay S, Timms T, Clark M, et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol. 2002;89:1205\u20137.","journal-title":"Am J Cardiol"},{"key":"181_CR6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425\u201335.","journal-title":"N Engl J Med"},{"key":"181_CR7","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437\u201345.","journal-title":"JAMA"},{"key":"181_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","volume":"53","author":"JG Robinson","year":"2009","unstructured":"Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"181_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410\u20138.","journal-title":"N Engl J Med."},{"key":"181_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149\u201358.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"181_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2165\/00003495-200464002-00005","volume":"64","author":"PS Sever","year":"2004","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004;64(Suppl 2):43\u201360.","journal-title":"Drugs"},{"key":"181_CR12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301\u20137.","journal-title":"N Engl J Med."},{"key":"181_CR13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jacl.2015.11.010","volume":"10","author":"RK Wadhera","year":"2016","unstructured":"Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol. 2016;10:472\u201389.","journal-title":"J Clin Lipidol"},{"key":"181_CR14","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"181_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"181_CR16","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2531\u201340.","journal-title":"J Am Coll Cardiol"},{"key":"181_CR17","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311:1870\u201382.","journal-title":"JAMA"},{"key":"181_CR18","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"181_CR19","doi-asserted-by":"crossref","unstructured":"Stroes E, Robinson JG, Raal FJ, et al. Clinical equivalence of evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies. Presented at: European Society of Cardiology Congress; August 29\u2013September 2, 2015; London, United Kingdom.","DOI":"10.1016\/j.cjca.2015.07.619"},{"key":"181_CR20","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","volume":"68","author":"JG Robinson","year":"2016","unstructured":"Robinson JG, Huijgen R, Ray K, Persons J, Kastelein JJ, Pencina MJ. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol. 2016;68:2412\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"181_CR21","unstructured":"Repatha\u00ae (evolocumab) prescribing information, Amgen."},{"key":"181_CR22","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of cardiology task force on expert consensus decision Pathways. J Am Coll Cardiol. 2017;70:1785\u2013822.","journal-title":"J Am Coll Cardiol"},{"key":"181_CR23","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jacl.2017.05.001","volume":"11","author":"CE Orringer","year":"2017","unstructured":"Orringer CE, Jacobson TA, Saseen JJ, et al. Update on the use of PCSK9 inhibitors in adults: recommendations from an Expert Panel of the National Lipid Association. J Clin Lipidol. 2017;11:880\u201390.","journal-title":"J Clin Lipidol"},{"key":"181_CR24","first-page":"2245","volume":"38","author":"U Landmesser","year":"2017","unstructured":"Landmesser U, Chapman MJ, Farnier M, et al. European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2017;38:2245\u201355.","journal-title":"Eur Heart J"},{"issue":"1","key":"181_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"181_CR26","first-page":"1270","volume":"23","author":"J Menzin","year":"2017","unstructured":"Menzin J, Aggarwal J, Boatman B, et al. Ezetimibe use and LDL-C goal achievement: a retrospective database analysis of patients with clinical atherosclerotic cardiovascular disease or probable heterozygous familial hypercholesterolemia. J Manag Care Spec Pharm. 2017;23:1270\u20136.","journal-title":"J Manag Care Spec Pharm"},{"key":"181_CR27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","volume":"2","author":"MJ Koren","year":"2017","unstructured":"Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2017;2:598\u2013607.","journal-title":"JAMA Cardiol"},{"key":"181_CR28","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580\u201390.","journal-title":"JAMA"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-020-00181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-020-00181-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-020-00181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T10:28:26Z","timestamp":1716200906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-020-00181-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,20]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["181"],"URL":"https:\/\/doi.org\/10.1007\/s40119-020-00181-8","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,20]]},"assertion":[{"value":"17 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}